Clinical trials: Adnexal Tumor
Ovarian Cancer
Role of Laparoscopy in Assessing Resectability of Ovarian Cancer
Aim of Work is Prevention of unnecessary laparotomies and failed attempts to perform optimal cytoreduction in women with advanced ovarian cancer.
- Trial name
- NCT05564234
- Testing
- laparoscopy then primary cytoreductive surgery, laparoscopy then neoadjuvant chemotherapy followed by interval cytoreductive surgery
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Zagazig University
Bladder Cancer, Brain and Central Nervous System Tumors
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer
- Trial name
- NCT00313599
- Testing
- lapatinib, paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Ovarian Cancer, Prostate Cancer
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
This study will evaluate patients' experiences with having gynecologic or prostate medical oncologists and surgeons offer them genetic testing, and having genetic counselors return the test results to patients over the telephone.
- Conditions
- Ovarian Cancer, Prostate Cancer, Pancreas Cancer
- Trial name
- NCT02917798
- Testing
- Assessments
- Where
- 5 sites in United States
- Volunteers
- 1,047 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III and IV , BRCA mutations or HRD positive epithelial…
- Trial name
- NCT06541314
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Hospital of Shandong University
Gynecologic Cancer, Gynecologic Neoplasm
The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study
This study compares traditional follow-up of gynaecological cancer patients to an alternative follow-up model. In the alternative follow-up model the patients will meet a nurse at every second consultation.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasm, Ovarian Cancer, Endometrial Cancer
- Trial name
- LETSGO (NCT04122235)
- Testing
- LETSGO follow-up
- Where
- 12 sites in Norway
- Volunteers
- 755 people
- Sponsor
- Sorlandet Hospital HF
Fallopian Tube Carcinoma, Recurrent Ovarian Cancer
Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer
This phase I trial studies the side effects and best dose of lenvatinib mesylate when given together with paclitaxel in treating patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Fallopian Tube Carcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Carcinoma, Recurrent Endometrial Cancer
- Trial name
- NCT02788708
- Testing
- Lenvatinib Mesylate, Paclitaxel, Pharmacological Study
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Floor Backes
Ovarian Cancer, Breast Cancer
Lynne Cohen Consortium Project: Multi-Center Database/Registry
Goals of this registry: 1.1 To collect and store very limited demographic information (age, birthdate, race and ethnicity), limited cancer risk and breast and ovarian disease history, as well as limited family history of breast…
- Trial name
- NCT00776958
- Testing
- Questionnaire
- Where
- 4 sites in United States
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Neoplasms
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.
- Trial name
- NCT00051948
- Testing
- TLK286
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Telik
Ovarian Cancer
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled
- Trial name
- NCT06188455
- Testing
- Fluzoparib Capsules, Apatinib Mesylate Tablets
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Ovarian Cancer
IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC
The study will be conducted in women with advanced (stage IIIa-IV) ovarian cancer of the histologic subtype high grade serous carcinoma (HGSOC) who are going through a diagnostic laparoscopy.
- Trial name
- IMPACT (NCT03378297)
- Testing
- Metformin, Acetylsalicylic acid, Olaparib
- Where
- 2 sites in Norway
- Volunteers
- 26 people
- Sponsor
- Haukeland University Hospital
Polycystic Ovary Syndrome
The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women
This is a placebo controlled trial investigating the effect of 6 months atorvastatin 20mg/day therapy on androgens, glucose metabolism and inflammatory markers in women with PCOS.
- Trial name
- NCT01072097
- Testing
- Atorvastatin
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- University of Oulu
Ovarian Cancer, Adverse Effects
Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Patients with early and advanced stages of epithelial ovarian cancer are treated with postoperative systemic chemotherapy after appropriate surgical staging and cytoreductive surgery.
- Trial name
- NCT01824615
- Testing
- Sunitinib
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Cathay General Hospital
Ovarian Cancer
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional…
- Trial name
- NCT00179725
- Testing
- CC-5013, liposomal doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene Corporation
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Ovarian Neoplasms
Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer
This is an observational prospective study. Patients diagnosed with advanced epithelial ovarian cancer (stage IC or higher) since 2008 will be asked to participate in this study by signing an informed consent.
- Trial name
- FindBRCANess (NCT02524808)
- Where
- 4 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Fundación de investigación HM
Ovarian Cancer
Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125
In 2015 the Danish Health authorities initiated major changes in the national follow-up (FU) program for ovarian cancer patients. The new FU program argues that there is no effect of routine monitoring of tumour marker CA125.
- Trial name
- NCT03004391
- Where
- Denmark
- Volunteers
- 25 people
- Sponsor
- Vejle Hospital
Ovarian Neoplasms
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
Four phase III trials in ovarian cancer consistently showed that front-line poly(ADP-ribose) polymerase (PARP) inhibition can significantly improve progression-free survival.
- Trial name
- NCT05440578
- Testing
- olaparib plus bevacizumab maintenance therapy
- Volunteers
- 50 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer
- Trial name
- NCT00003926
- Testing
- amifostine trihydrate, busulfan, filgrastim
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated…
- Trial name
- NCT07069335
- Testing
- Olaparib 150 MG
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Platinum-resistant Ovarian Cancer
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer.
- Trial name
- NCT04718376
- Testing
- Mitoxantrone Hydrochloride Liposome, intravenous injection (IV)
- Where
- 7 sites in China
- Volunteers
- 56 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.